-
-
-
-
-
-
-
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
-
-
-
-
-
-
-
IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia
-
-
-
-
-
-
-
BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene’s TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets
-
-
-
-
-
-
-
BeiGene Reports Second Quarter 2021 Financial Results
-
-
-
-
-
15,424 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

